fda semaglutide compounding enforcement november 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified FDA issues warning about some

A European 2-year multicenter trial observed significant weight regain in patients who discontinued orlistat and switched to placebo compared with those who continued [16]

Most provinces cover GLP-1 medications for Type 2 diabetes but not specifically for obesity treatment

CEO David Ricks framed it directly: We are not just discovering the medicines of the future

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (736 amide) in type 2 (non-insulin-dependent) diabetic patients

While they offer remarkable benefits, you might be hearing more about their potential side effects, especially concerning gallbladder problems

Because the causes of inflammation vary widely, GLP-1 and GLP-1/GIP medications meaningfully improve some inflammatory pathways (especially metabolically driven inflammation)but not all., This guide explains: How inflammation shows up in different organ systems Which inflammatory pathways semaglutide and tirzepatide actually improve Why they do not treat autoimmune disease, fibromyalgia, or chronic pain What early research suggestsand why we must be cautious What Is Inflammation